Evidence Grade D — Primarily preclinical. 11 published studies, mostly animal models. 0 registered clinical trials.
Medically reviewed by a licensed medical professional
Matrixyl is a cosmetic peptide ingredient widely used in anti-ageing skincare products to stimulate collagen production. It mimics a natural collagen fragment that signals skin cells to make new collagen. Among cosmetic peptides, it has one of the stronger evidence bases — the largest randomised controlled cosmetic peptide trial (93 subjects) showed significant wrinkle improvement. It has no pharmaceutical approval.
Matrixyl is also known by these brand and alternate names:
11 published studies: 7 human, 1 animal, 4 in-vitro, 0 reviews
Matrixyl has no pharmaceutical authorisation. It is one of the better-studied cosmetic peptides, with the largest randomised controlled cosmetic peptide trial to date (93 subjects, double-blind, 12 weeks) demonstrating significant wrinkle improvement versus vehicle.
Among cosmetic peptides, Matrixyl has a relatively robust evidence base for topical skin appearance improvement. However, these are cosmetic efficacy studies, not pharmaceutical trials, and the standards of evidence differ significantly. Matrixyl is a topical cosmetic ingredient — this context should be distinguished from injectable peptide use.
Research suggests Matrixyl acts as a 'matrikine' — a peptide fragment from collagen breakdown that signals fibroblasts to produce new collagen. The palmitoyl (fatty acid) group enhances skin penetration and cell membrane interaction. In vitro studies report increased production of collagen types I, III, and IV, as well as fibronectin and hyaluronic acid. These laboratory observations have been partially supported by controlled cosmetic trials.
Research suggests the Robinson 2005 study (93 subjects, double-blind, 12 weeks) provides meaningful evidence of cosmetic efficacy — the best-designed trial for any cosmetic peptide. Laboratory studies show increased production of multiple collagen types and other skin structural proteins. However, the trial was conducted by the company that markets the ingredient, and independent replication is limited. As with all cosmetic peptide claims, these are skin appearance improvements from topical formulated products — a very different context from injectable use.
PeptideTrace tracks 0 registered clinical trials for Matrixyl sourced from ClinicalTrials.gov.
No trials registered on ClinicalTrials.gov for this compound.
Matrixyl (Palmitoyl Pentapeptide-4, Pal-KTTKS) is a 5-amino acid lipopeptide with the sequence Pal-Lys-Thr-Thr-Lys-Ser. Its molecular weight is 802.05 Da (CAS 214047-00-4). Developed by Sederma (now Croda), Matrixyl is a palmitoylated derivative of the pentapeptide KTTKS, which is a fragment of the procollagen I C-terminal propeptide. The palmitoyl group enhances lipophilicity for improved skin penetration. It is the active peptide in Olay Regenerist and numerous other cosmetic formulations.
Research suggests Matrixyl functions as a matrikine — a peptide fragment from extracellular matrix proteins that signals cells to produce new matrix components. The KTTKS sequence mimics a procollagen I breakdown product and signals fibroblasts via the TGF-beta pathway to upregulate synthesis of collagen types I, III, and IV, fibronectin, elastin, and hyaluronic acid. The palmitoyl group facilitates passage through the stratum corneum via the intercellular lipid pathway. This matrikine mechanism is distinct from neuromuscular peptides like Argireline: rather than relaxing muscles, Matrixyl stimulates structural protein production.
Robinson et al. (2005) conducted the largest cosmetic peptide RCT to date (N=93, double-blind, 12 weeks), demonstrating significant wrinkle and fine line improvement versus vehicle. Lintner (2002, 28-day study) reported fold depth reduction of 18%, thickness reduction of 37%, and rigidity reduction of 21%. Manufacturer comparisons suggest Matrixyl at 3 ppm concentration produces effects comparable to 700 ppm retinol with better tolerability. These findings supported its adoption as the key active in Procter & Gamble's Olay Regenerist line.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 3 vendor listings
View pricing data across vendors and countries for Matrixyl
GHK has no pharmaceutical authorisation. Small cosmetic studies of the copper-complexed form (GHK-Cu) have reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable use have been completed. As with GHK-Cu (#85), the cosmetic evidence base for topical use should be distinguished from claims about injectable use. Gene expression profiling studies have reported broad effects, but observational genomic changes do not constitute evidence of therapeutic efficacy. This entry overlaps substantially with GHK-Cu (#85).
Argireline has no pharmaceutical authorisation. It is widely available as a cosmetic ingredient in over-the-counter skincare products. Small industry-sponsored studies have reported wrinkle depth reductions of 17–30% with topical application. The key scientific question is whether sufficient peptide penetrates intact skin to reach neuromuscular junctions and produce a meaningful effect. The molecule's size exceeds the conventional limit for transdermal absorption. Argireline's cosmetic use in formulated skincare products represents a fundamentally different risk profile from injectable use.
GHK-Cu has no pharmaceutical authorisation from any regulatory agency. It is widely available as a cosmetic ingredient in over-the-counter skincare products, where it is marketed for skin conditioning. A small study comparing GHK-Cu cream to vitamin C and retinoic acid creams reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable GHK-Cu have been completed. The compound's cosmetic use (topical, in formulated skincare products) should be clearly distinguished from its unregulated availability as an injectable research compound. These represent fundamentally different risk profiles.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
